Close

Nephros Announces Strategic Collaboration with Biocon 1, LLC

RIVER EDGE, NJ, November 18, 2015 /Businesswire/ — Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, announced today that it has initiated a strategic collaboration with Biocon 1, LLC, a commercial water purification company that markets the AETHER® Water Systems technology, expanding the use of Nephros technology into the food service industry and the use of Biocon technology into the medical industry.

Biocon 1’s AETHER® Water Systems technology, which includes patented water filtration media and water filtration products, provides solutions for customers to address all contaminate issues and to provide clean-tasting, sediment-free, scale-free, and bacteria-free water for the food service industry. AETHER® Water Systems are used with ice machines, coffee stations, and soda fountains in hotels, casual dining restaurants, fast food restaurants and convenience stores. Nephros will provide Biocon 1 with a bacteria control filter cartridge to integrate with its AETHER® line of filtration products. As part of the collaboration, Nephros will have access to Biocon’s anti-scale and related water filtration technology to develop filter products for the medical industry.

“We look forward building a strong partnership with Biocon,” said Daron Evans, President and CEO of Nephros. “We are impressed by their technology and their growing foot print in the food service industry. We believe that Biocon is the right partner to help Nephros begin to expand our ultrafiltration business outside of the medical space, while providing the potential to enhance our product offering to our medical customers.”

“We have a proven track record of providing our customers with filtration technology that provides a superior performance to the well-known brands in the market,” said Greg Lucas, President and CEO of Biocon 1, LLC. “Integrating the Nephros bacteria control technology into our AETHER® Water Systems will enable us to continue to stay ahead of the technology curve – designing and engineering our product platform to provide customized solutions for our customers in the food, beverage, and hospitality industries. Using the combined technology arc from the two companies positions our portfolio of products as a turnkey solution for customers that want superior technology to solve their water contaminate issues.”

About Nephros, Inc.

Nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters, as well as a hemodiafiltration system for the treatment of patients with end stage kidney disease. Its filters, which it calls ultrafilters, are used primarily in medical applications. Nephros ultrafilters are used by dialysis centers for the removal of biological contaminants from the water and bicarbonate concentrate feeding hemodialysis devices. Additionally, Nephros ultrafilters are used in hospitals and medical clinics as an aid in infection control by retaining bacteria (i.e. Legionella, Pseudomonas), virus and endotoxin from water used by patients.

For more information about Nephros, please visit the company’s website at www.nephros.com.

About Biocon, LLC

Biocon 1, LLC, doing business as Aether Water Systems, is a privately-held commercial water treatment company that develops and sells high performance water and air purification systems to the food service industry, as well as other air and gas filtration markets. Biocon’s patented technology and assets are based on engineered innovations that effectively control biofilm, bacteria, scale and other water related issues.

For more information about Aether Water Systems, please visit the company’s website at www.aetherfilters.com

Forward-Looking Statements

This release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding potential business stemming from the strategic relationship between Biocon 1, LLC and Nephros, and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Nephros Inc.’s reports filed with the U.S. Securities and Exchange Commission, including with respect to Nephros, its Annual Report on Form 10-K for the year ended December 31, 2014. Nephros, Inc. does not undertake any responsibility to update the forward-looking statements in this release.

Contact:

Investor:

PCG Advisory Group

Kirin M. Smith, Chief Operating Officer

Direct: 646-863-6519

www.pcgadvisory.com